2020 Annual Virtual PME Symposia

Round out your CMHC Live Online educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies.

WEDNESDAY, OCTOBER 21, 2020 · 12:00 – 1:00 PM Eastern Time

The Interconnected Cardio-Renal-Metabolic (CRM) Systems

Presenters: Eden Miller, DO; Kris Vijay, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc and Lilly USA, LLC.

Program Description:

Information to come.

WEDNESDAY, OCTOBER 21, 2020 · 6:30 – 7:30 PM Eastern Time

An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C

Presenter: Eliot A. Brinton, MD, FAHA, FNLA, FACE

Sponsored by Esperion Therapeutics.

Program Description:

This session will cover the following information:

  • Cardiovascular disease and its mortality and morbidity
  • Unique mechanism of action for two treatment options
  • Efficacy data for two treatment options
  • Safety data for two treatment options
  • Overview of the ongoing Outcomes trial

THURSDAY, OCTOBER 22, 2020 · 12:25 – 1:25 PM Eastern Time

Atherosclerotic Cardiovascular Disease (ASCVD) in Diabetes: Identifying High Risk and the Importance of Reducing the Burden of Elevated LDL-C Levels

Presenter: Yehuda Handelsman, MD

Sponsored by Novartis.

Program Description:

This program highlights the burden of cardiovascular disease in patients with diabetes who have an elevated risk of ASCVD and cardiovascular events. The mechanistic role of elevated LDL-C in ASCVD progression and the importance of lowering LDL-C levels is emphasized, and the use of LDL-C–lowering therapies to reduce risk in patients with diabetes is described, in context with currently published guidelines.

THURSDAY, OCTOBER 22, 2020 · 5:20 – 6:20 PM Eastern Time

VASCEPA® (icosapent ethyl): Elevating the Standard of Care

Presenter: Matthew Budoff, MD, FACC, FAHA

Sponsored by Amarin Pharma, Inc.

Program Description:

There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a groundbreaking therapeutic option to elevate the current standard of care.

FRIDAY, OCTOBER 23, 2020 · 12:00 – 1:00 PM Eastern Time

Close to the Heart: The Importance of Recognizing Cardiovascular Risk in Type 2 Diabetes

Presenter: John E. Anderson, MD

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Program Description:

The objective of this program is to communicate the importance of addressing cardiovascular risk in patients with type 2 diabetes. The program will cover data on prevalence, morbidity, mortality, and intensive versus conventional glucose lowering on macrovascular complications. In addition, the program will review guidance from leading medical associations that is based upon completed cardiovascular outcome trials of antihyperglycemic medications in patients with type 2 diabetes.